GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Milei Threatens Falkland Oil Firms With Sanctions 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Anthropic IPO Marketing Expected to Start in Mid-October 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Add as a preferred source on Google
ROCKVILLE, Md., Feb. 27, 2018 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, March 6, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2017 and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 1584469. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT:
Investors
Natalie Wildenradt, 646-681-8192
[email protected]
Media
Adam Pawluk, 202-591-4063
[email protected]
